• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Evolv Launches GLP-1 Supplement, a Natural Alternative to Weight-Loss Drugs

by Jasmine Pennic 09/10/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Pioneering biomimetics company Evolv introduces its first product Evolv GLP-1: the first ingestible, natural GLP-1 peptide designed for effective and accessible weight management

– The oral GLP-1 supplement was created using a proprietary yeast strain engineered to produce a new molecule that delivers the full power of GLP-1 naturally. Unlike synthetic drugs, this non-habituating supplement is designed to help individuals manage appetite and metabolism without the side effects or high costs.

Biomimetics: The Next Frontier in Wellness

Evolv GLP-1’s single active ingredient, EV1 Peptide, is made of canonical amino acids. The product uses a proprietary yeast powder, derived from yeast hydrolysate, which is clinically shown to activate the body’s natural GLP-1 production. The formula is natural, vegan, allergen-free, and manufactured in the U.S. in a cGMP-compliant facility.

With the introduction of Evolv GLP-1, the company is defining a new category of health technology: biomimetics. These are biologically engineered molecules designed to mimic and enhance the body’s natural functions. Unlike synthetic compounds, biomimetics are created using food-safe organisms from nature, making them free of stimulants, habit-forming ingredients, and unwanted side effects.

Evolv’s biomimetics are the result of a world-class team of scientists and bioengineers with deep expertise in synthetic biology and molecular design. The team, led by co-founders Kwang-Chul Kwon, PhD, and Cory Henderson, PhD, uses AI-driven molecular modeling to develop its innovative solutions.


A Natural Solution for a Growing Health Crisis

Over 73% of U.S. adults are overweight, and millions have sought solutions in synthetic GLP-1 drugs. While these drugs have increased in popularity, many people face barriers such as high costs and adverse side effects due to the extreme doses. Evolv aims to change this with a different approach.

Evolv GLP-1 provides lasting appetite control, reduces “food noise,” and enhances metabolic function to support steady energy. By balancing hunger signals, improving digestion, and optimizing nutrient absorption, it is designed for healthy individuals seeking an effective weight management solution, not for the treatment of disease.

Third-Party Testing & Clinical Trails

Evolv GLP-1 has undergone third-party testing for purity, potency, and safety, with three studies completed and a fourth clinical trial currently underway. These studies have measured both safety and efficacy across key biomarkers related to appetite regulation, metabolic function, and nutrient absorption.

“GLP-1 is a natural hormone found in your body that helps signal fullness and satiety. We’ve created a product that mimics the effects of GLP-1, helping you feel fuller longer, and allowing you to approach your nutrition and food choices with a sense of calm intention, rather than impulsive craving,” said Becca McCarthy, MBA, co-founder, president, and chief operating officer of Evolv. “This isn’t just another supplement. We’re building a new category at the intersection of biology and accessibility to reimagine how people take control of their metabolism, appetite, and longevity with solutions that deliver real results and work with the body—not against it.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: GLP-1

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Doctors Don’t Buy Medical Tech Anymore. IT Does.

Best Practices for IT and Clinical Collaboration in Medical Tech Implementation

Most-Read

Microsoft Copilot Health, Integrates Apple Health, Oura, and 50,000 EHRs in New AI Push

Microsoft Launches Copilot Health, Integrates Apple Health, Oura, and 50,000 EHRs in New AI Push

Health Recovery Solutions (HRS) Acquires Rimidi for Chronic Care Management and RPM Integration

Health Recovery Solutions (HRS) Acquires Rimidi for Chronic Care Management and RPM Integration

RadNet Subsidiary DeepHealth Acquires French Radiology AI Leader Gleamer

RadNet’s $269M AI Play: DeepHealth Acquires French AI Gleamer

Walgreens Launches Virtual Weight Management Platform for Self-Pay GLP-1 Patients

Walgreens Launches Virtual Weight Management Platform for Self-Pay GLP-1 Patients

KLAS Digital Pathology 2026 Report: Top IMS, Scanner, and AI Vendors Evaluated

KLAS Digital Pathology 2026 Report: Top IMS, Scanner, and AI Vendors Evaluated

The "Platform" Squeeze: Epic Releases Native AI Charting, Putting Venture-Backed Scribes on Notice

The “Platform” Squeeze: Epic Releases Native AI Charting, Putting Venture-Backed Scribes on Notice

Analysis: Oracle Cerner’s Plans for a National EHR

Oracle May Cut 30k Jobs and Sell Cerner to Fund $156B OpenAI Deal

The $1.9B Exit: Why CommonSpirit is Insourcing Revenue Cycle and Tenet is Betting Big on Conifer AI

The $1.9B Exit: Why CommonSpirit is Insourcing Revenue Cycle and Tenet is Betting Big on Conifer AI

KLAS 2026 Rankings: Aledade and Guidehealth Named Top VBC Enablement Firms

KLAS 2026 Rankings: Aledade and Guidehealth Named Top VBC Enablement Firms

Beyond the Hype: New KLAS Data Validates the Financial and Clinical ROI of Ambient AI

Beyond the Hype: New KLAS Data Validates the Financial and Clinical ROI of Ambient AI

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |